Roche Annual General Meeting 2024

All proposals of the Board of Directors approvedSeverin Schwan re-elected as Chairman of the Board of Directors; all other Board members standing for election confirmed37th consecutive dividend increase to CHF 9.60 per shareBasel, 12 March 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its shareholders had approved all proposals of the Board of Directors at its Annual General Meeting. The 635 shareholders in attendance, who represented 77.02% of the total 106,691,000 shares, approved the Annual Financial Statements and Co nsolidated Financial Statements for 2023, the Remuneration Report and the Sustainability Report.Severin Schwan was re-elected as Chairman of the Board of Directors by 97.75% of the votes. Addressing the shareholders in a speech, he said:" Both the Pharmaceuticals and Diagnostics Divisions delivered strong results in 2023. In particular, I would like to emphasise the strong development of our base business. As a result, we grew on a currency-adjusted basis - despite the significant decline in sales of COVID-19 products. We have a broad product pipeline with 82 drug candidates, ten of which are already in the final phase of clinical development. We have a strong presence in the key areas of oncology, immunology and neurology. We are also expanding into new areas, including obesity. In our Diagnostics Division, we will launch more new products in 2024 than ever before. We are well positioned for the future. "In addition, shareholders approved ...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news